Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

NCT05218499 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Liposarcoma, Dedifferentiated

Interventions

DRUG: Brigimadlin
DRUG: Doxorubicin

Sponsor

Boehringer Ingelheim